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Abstract
Background: Millions of lives around the world are being saved annually through blood transfusion. However,
blood transfusion is among the essential vehicles for transmitting infections. The overall prevalence of Transfusion
Transmissible Infections among blood donors differs around the world, reflecting the variation in the prevalence of
these infections. This study aims to assess the prevalence and trends of Transfusion Transmissible Infections among
blood donors in Qatar.
Methods: This is a cross-sectional study utilizing donation records of 5 years from January 2013 to December 2017.
We included in the study results for all screening and confirmatory tests for Hepatitis B Virus, Hepatitis C Virus,
Human T-lymphotropic Virus-I/II, Syphilis and Malaria.
Results: Among the 190,509 donations received at the donation centre during the study period, about 91% of
donations were received from males and 9% from females. The overall positivity rate for all tests was 1.87, 2.23, 1.78,
2.31, 2.67% for the years 2013 through 2017, with an increasing yearly trend by 6% each year. The overall positivity
rates for Hepatitis C Virus, Human T-lymphotropic Virus-I/II, Hepatitis B Virus, Syphilis and Malaria (2013–2017) were
0.60, 0.18, 0.30, 0.43 and 0.20%, respectively.
Conclusion: The overall positivity rate of all tests combined for the Transfusion Transmissible Infections
demonstrated a gradually increasing trend from 2013 to 2017. However, the trend for each infection (Hepatitis C
Virus, Hepatitis B Virus, Syphilis and Malaria) was fluctuating except for Human T-lymphotropic Virus-I/II, which was
increasing. Supporting the development of effective prevention and control strategies requires further
comprehensive investigations for better estimation of the burden of these infections.
Keywords: Blood Donors, Transfusion, Hepatitis B virus, Hepatitis C virus, Human T-Lymphotropic virus, Syphilis,
Malaria, Qatar
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Background
Blood transfusion is a life-saving procedure that saves
millions of lives every year around the world, it can be
transfused as whole blood for one patient or may be
manufactured into blood-derived products to be pro-
vided for more than one patient. However, it is known
that blood transfusion can be associated with risks of
transmitting certain infections [1, 2].
These infections are known as Transfusion Transmis-
sible Infections (TTIs), which defined as any infection
that can be transmitted from person to person through
parenteral administration of blood or any blood prod-
ucts. Thus, different outcomes may follow unsafe trans-
fusion, as it can cause an acute clinical sickness; it can
persist in the receiver as a carrier or cause asymptomatic
infection [3].
These infections include viral, bacterial, parasites and
prions. The most prominent among these are, Human Im-
munodeficiency Virus (HIV), Hepatitis B Virus (HBV) and
Hepatitis C Virus (HCV), due to their high prevalence
rates. Other agents are Human T-cell Lymphotropic Virus
(HTLV-I/II), Cytomegalovirus (CMV), Parvovirus B19,
West Nile Virus (WNV) and Dengue Viruses, Trypano-
somiasis, Malaria and Transmissible Spongiform Enceph-
alopathy (TSE) [4].
The prevalence of TTIs among blood donations varies
between high and low-income countries. It was reported
that the prevalence of HIV, HBV, HCV and Syphilis in
high-income countries are 0.003, 0.03, 0.02 and 0.05%,
respectively. While in low-income countries, the preva-
lence of these infections is higher; 1.08, 3.70, 1.03 and
0.90%, respectively. These differences reflect the vari-
ation in the prevalence of these infections among the
populations of these countries [5]. These variations are
also observed between the World Health Organization
(WHO) regions. As African and Pacific regions are the
highest in HBV prevalence, Eastern Mediterranean re-
gion is the highest for HCV prevalence, Sub-Saharan Af-
rica is the highest for malaria, and scattered foci in
southwestern Japan, Colombia and intertropical Africa
are endemic for HTLV-1 [6–8].
Many global efforts are provided to ensure the safety
of the whole blood transfusion process. These efforts in-
clude providing recommendations and guidelines to es-
tablish a national blood screening and surveillance
system for the entire transfusion chain, i.e. haemovigi-
lance system. Moreover, efforts are also provided for the
establishment of the Global Database on Blood Safety
(GDBS), aiming to improve transfusion services globally
[9, 10].
In Qatar, Expatriates comprised a high proportion of
Qatar’s population, coming from all over the world, with
diverse and unique epidemiological characteristics for
each region. Enormous efforts aimed at protecting the
health of the population and prevention the spread of in-
fectious diseases from newcomers. Among these efforts
is the law that mandates all newcomers wishing to work
and live in Qatar to undergo a medical exam and infec-
tious diseases screening to be able to receive a residence
permit. Furthermore, specific job categories, including
health care personnel and food industry workers, are re-
quired to undergo annual medical check-ups.
The Blood Donor Center at Hamad Medical Corpor-
ation (HMC) is responsible for the provision of safe
blood supply through the efforts provided to ensure that
donated blood is free from infections. However, few
local epidemiological studies are assessing the prevalence
and trends of transfusion-transmitted infections among
blood donors, comprehensively. Hence, conducting this
study to assess transfusion transmissible infections
among blood donors can provide a better understanding
of the epidemiology of these infections, which can sup-
port strategies development to evaluate safe blood sup-
ply measures, in addition to the preventive and control
measures that are needed to manage the burden of these
infections in the community. Therefore, the study aims
to assess the prevalence and the trends of the transfu-
sion transmissible infections among blood donors during
the period 2013–2017, in Blood Donor Center at HMC
in the State of Qatar.
Methods
Study setting
The Division of Transfusion Medicine includes the Blood
Bank Section & Donor Unit. The Transfusion Division is
the only provider of blood and blood components in the
State of Qatar. Its main function is to assure the availabil-
ity of safe blood whenever needed. The centre follows
international recommendations for the provision of safe,
efficacious blood products and transfusion. In September
2017, HMC’s committee for blood transfusion announced
a new program for monitoring blood transfusion process
in the country. The Centralized Hemovigilance Program
aims to improve the quality of the blood transfusion chain,
with the main focus on safety.
The program was initially implemented at HMC and
was introduced across all healthcare facilities around the
country, that collect, use or store blood and its products.
All donated unit samples undergo screening tests prior
transfusion for the following infectious, through follow-
ing methods: Chemiluminescent Microparticle Immuno-
assay (CMIA) by (ARCHITECT, Abbott laboratories) for
detecting HIV Ag/Ab, HBsAg. In addition to antibodies
for HTLV-I/II, Syphilis TP, HCV, HBsAg and anti-HBc.
Confirmatory tests are performed through Line Immuno
Assay (LIA) by (FUJIREBIO, Europe N.V.) as a confirma-
tory test for the presence of these antibodies. Moreover,
(ARCHITECT, Abbott laboratories) Malaria Ag P.f/Pan
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and Enzyme-linked Immunosorbent Assay (ELISA) by
(NOVA TEC IMMUNOIAGNOSTICA, GmpH) are
used for determination of Plasmodium antigens and
antibodies, respectively.
Data collection
This is a cross-sectional study, conducted using data of
all blood donations received in the period between Janu-
ary 2013 and December 2017 at Blood Donor Center in
HMC. All data included in the study were retrieved from
the records anonymously with no identifications of the
donors. An extraction sheet was used, and data were
provided only as frequencies of positive results for each
screening test, in addition to basic demographics includ-
ing age, gender and nationality of all donors. Tests in-
cluded in this study were: HBsAg, HBcAb, HBV NAT,
HCV Ab, INNO-LIA HCV, HCV NAT, HTLV-I/II Ab,
INNO-LIA HTLV-I, Syphilis Ab and INNO-LIA Syph-
ilis, in addition to Malaria Ab and Ag tests. Data for
HIV were not included due to its sensitivity, complexity,
need for careful handling and unique address with a spe-
cific and comprehensive approach.
Data Analysis
Data were extracted from the records and entered to
Microsoft excel. Frequencies and percentages were used
for the description of blood donors by gender, age
groups and nationality. Furthermore, the analysis was
conducted to assess the positivity rate of the transfusion
transmissible infections distribution by age groups, gen-
der, and nationality (Qataris and Non-Qataris). Infec-
tions positivity rates were calculated for each year to
identify trends throughout the 5 years. Categorical vari-
ables were compared using the χ2 test. Test for trend p-
value was obtained using multivariable Poisson regres-
sion with robust variance modelling the rate of positive
tests to year (as a continuous variable) adjusting for age
and using the proportion of donors in the population as
an offset. P-values less than 0.05 were considered statis-
tically significant, and Stata/ SE version 15 was used to
conduct the analysis.
Results
A total of 190,509 donations were received at Blood
Donor Centre in HMC in the period between January
2013 and December 2017. About 91% of the donations
were received from males and 9% from females (Table 1).
Moreover, donors of the age group 31–40 years were the
highest to donate blood, with a percentage of 38.6% of the
total donations during the study period (Table 1). Qataris
were among the top six nationalities to donate blood in all
years of the study (Fig. 1).
The positivity rates for all the tests combined (i.e.
screening and confirmatory) were: 1.87, 2.23, 1.78, 2.31,
2.67% for the years 2013, 2014, 2015, 2016 and 2017, re-
spectively (Fig. 2). Multivariable Poisson regression ana-
lysis showed that compared to the year 2013, the age-
adjusted incidence rate ratio of positivity for years 2014,
2015, 2016 and 2017 were 1.24, 1.02, 1.24 and 1.32, re-
spectively. The average age-adjusted rate of positives
tests significantly increased by 6% each year (P < 0.001).
Furthermore, the positivity rates for tests combined
were compared between male and female donors. Re-
sults showed that the rates were more among male do-
nors in 2013 through 2015, which was significant only
for 2013 and 2014 (P < 0.001). However, in 2016, the
rates were significantly higher among females (P <
0.001), but the difference was again higher among male
donors (P = 0.056) in 2017 (Fig. 3).
Assessing the positivity rates among age groups
showed that the rates were higher among young donors,
except for the years 2013 and 2014, in which the rates
Table 1 Demographic characteristics of blood donors in Blood Donor Center at HMC in the period 2013 2017
Year 2013 2014 2015 2016 2017 Total
Total Donations 26,153 38,577 42,528 40,865 42,386 190,509
N (%) N (%) N (%) N (%) N (%) N (%)
Gender
Male 24,140 (92.3) 34,961 (90.6) 38,531 (90.6) 37,028 (90.6) 38,577 (91.0) 173,237 (90.9)
Female 2013 (7.7) 3616 (9.4) 3997 (9.4) 3837 (9.4) 3809 (9.0) 17,272 (9.1)
Age Group
≤ 20 770 (2.9) 1276 (3.3) 1194 (2.8) 1357 (3.3) 915 (2.2) 5512 (2.9)
21–30 9035 (34.5) 13,341 (34.6) 14,598 (34.3) 13,847 (33.9) 13,131 (31.0) 63,952 (33.6)
31–40 10,044 (38.4) 14,609 (37.9) 16,112 (37.9) 15,706 (38.4) 16,974 (40.0) 73,445 (38.6)
41–50 4831 (18.5) 6977 (18.1) 7920 (18.6) 7424 (18.2) 8381 (19.8) 35,533 (18.7)
51–60 1337 (5.1) 2142 (5.6) 2429 (5.7) 2264 (5.5) 2644 (6.2) 10,816 (5.7)
> 60 136 (0.5) 232 (0.6) 275 (0.6) 267 (0.7) 341 (0.8) 1251 (0.7)
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were higher in older age groups (P < 0.001), (Table 2).
Moreover, when the rates were assessed according to na-
tionality throughout the years, it was found that these
rates were higher in Non-Qataris compared to Qataris
throughout all the study period (P < 0.001), (Fig. 4).
Furthermore, positivity rates of the screening tests were
found to be fluctuating over time, for HBV (P= 0.256), Mal-
aria (P= 0.523), Syphilis (P= 0.868) and HCV (P= 0.067).
However, trends were increasing for HTLV I/II from 0.08 to
0.23 (χ2 = 17.563 and P < 0.001) as shown in (Table 3).
Discussion
Even though blood transfusion saves millions of lives
every year, unsafe blood remains a threat to the spread
of infections. Moreover, it’s also important to address
the fact that safe blood is considered a universal right,
and it should not cause any harm. Thus, it should be
fully screened and ensured not be contaminated by any
transmissible infection [11].
Blood donation centres are among valuable sources of
data, as the prevalence of transfusion transmissible infec-
tions among blood donors differs throughout the world,
and it can indirectly reflect the burden variations among
these populations. This is because blood donors are usu-
ally representing the healthy members of the community
so that it can have its inferences on the general popula-
tion. Currently, the number of registered donors at
Blood Donor Center in HMC had increased noticeably
Fig. 1 Percentage of blood donations by nationality in Blood Donors Center at HMC in the period 2013–2017. *Others: Including all nationalities
together following the top six ranking nationalities for donation
Fig. 2 Temporal trend of total TTIs prevalence using combined serological and NAT screening (HBsAg, HBcAb, HBV NAT, HCV Ab, INNO-LIA HCV,
HCV NAT, HTLV-I/II Ab, INNO-LIA HTLV-I, Syphilis Ab and INNO-LIA Syphilis, in addition to Malaria Ab and Ag tests) among blood donors in blood
donors centre at HMC in the period 2013–2017
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as a result of the continuous promotion, motivation,
guidance, and education efforts about the importance of
blood donation, which led to the overall rise in the gen-
eral public awareness.
In this study, the predominance of blood donations
was by males, which was consistent with several studies
[12, 13]. Literature showed that women contribute less
to blood donations than men due to many factors, in-
cluding physiological factors such as menstruation, lacta-
tion and pregnancy [14]. However, some studies showed
that this difference between gender is much less [15, 16].
The predominance of males’ contribution to blood do-
nations was also observed in regards transfusion trans-
missible infections positivity rates, as this study showed
a consistent predominance throughout most of the
years, in which rates were higher in male donors. These
were similar to the findings from studies in the region
[17–20].
In general, the younger population seems to contribute
more to blood donation, as it was shown in several stud-
ies, in which most donors were less than 30 years in age
[12, 21, 22]. However, in this study, most of the blood
donors found to be aged 31–40 years old. Additionally,
positivity rates of infections were found to be more in
the younger population, which was also found in other
studies conducted in countries from different regions
[21–23].
In literature, it has been discussed that young males
are more to be involved in risky behaviours than females
and older age groups. Moreover, results from several
studies showed that some donors are involved in risky
behaviour activities, yet they contribute to blood dona-
tion. The reason is that they use it to check if they were
infected with any of the infections that can be related to
their risky behaviours [24–26].
In this study, the positivity rates of the combined tests,
including serological and NAT tests, were assessed
throughout the years 2013 to 2017. By assessing these
rates during this period, we were able to identify the
trend for these infections, which found to be an increas-
ing trend, after adjusting to age and the total population.
Despite this increasing trend, yet, the rates were less
than what was found in countries from different regions,
such as Saudi Arabia, Egypt, India and Nigeria [27–30].
Moreover, the positivity rates were also assessed for
selected tests throughout the study period. The results
showed a fluctuating trend for HBsAg, between 0.34 in
2013 and 0.29 in 2017. These rates are less than what
has been found in studies from countries in the region
including Saudi Arabia, Kuwait, Jordan and Egypt [31],
which can be attributed to the effective prevention and
control strategies including vaccination programs [32].
The rates for HCV Ab showed a changing trend be-
tween 0.58 in 2013 and 0.70 in 2017. However, these
rates are less than the reported from Egypt and Saudi
Arabia [33], which can be attributed to the high preva-
lence of the disease among the general population and
Fig. 3 Gender distribution of positivity rate for combined serological and NAT screening (HBsAg, HBcAb, HBV NAT, HCV Ab, INNO-LIA HCV, HCV
NAT, HTLV-I/II Ab, INNO-LIA HTLV-I, Syphilis Ab and INNO-LIA Syphilis, in addition to Malaria Ab and Ag tests) of blood donors in Blood Donors
Center at HMC in the period 2013–2017
Table 2 Age distribution of positivity rate (%) for TTIs combined
tests of blood donors in Blood Donors Center at HMC, 2013–
2017
Age Groups ≤ 20 21–30 31–40 41–50 51–60 > 60 P-value
2013 1.53 1.61 2.06 2.36 2.23 1.39 P < 0.001
2014 2.42 1.87 2.28 2.46 2.32 3.10
2015 2.48 1.47 1.59 1.84 1.63 2.32
2016 4.66 1.73 1.71 1.84 1.83 1.45
2017 6.35 1.72 1.80 1.86 1.54 3.02
Combined Tests: (HBsAg, HBcAb, HBV NAT, HCV Ab, INNO-LIA HCV, HCV NAT,
HTLV-I/II Ab, INNO-LIA HTLV-I, Syphilis Ab and INNO-LIA Syphilis, in addition to
Malaria Ab and Ag tests)
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the migration from these countries to other countries
with lower prevalence [34]. This was consistent with
findings from our study, as the rates were higher among
the Non-Qataris throughout the years. However, the
rates were higher than what was reported from other
countries in the same region (i.e. middle east region),
like Iran and Turkey [33].
Furthermore, screening for HTLV is also among the
recommended screening for transfusion, and this in-
cludes two viruses: I and II that differs in their geo-
graphical distribution and clinical disease association.
HTLV is endemic in some parts of the world, and in
some regions, the prevalence of the virus is very low, as
the situation here in Qatar.
The cost-effectiveness of the universal screening strat-
egies for HTLV has been argued. This was especially for
the screening implementation by high-income countries
with a low prevalence of the infection [35, 36]. Qatar is
among these countries. However, it is a destination for
working force from all around the world, including areas
endemic with the virus. Therefore, HTLV is among the
screening requirements for blood safety in the country.
The positivity rate for HTLV I/II Ab in 2017 found to
be 0.23, which represents an increasing trend from 0.08 in
2103. Further analysis for the findings showed that the
positivity rates were more in Non-Qataris than Qataris for
the screening test, but zero positivity among Qataris for
the confirmatory test (i.e. INNO-LIA), which is consistent
with epidemiological distribution of the disease, consider-
ing Qatar as low prevalence area for HTLV [7].
Donors can threaten blood safety with risky behaviour
as they may potentially acquire syphilis, among other in-
fections. In this study, the positivity rates for Syphilis Ab
among donors throughout the years showed a fluctuat-
ing trend that reported to be 0.48 in 2013 and to be 0.45
in 2017, and these rates were higher in Non-Qatari
throughout the years. Yet, these rates were less than
what was found in studies in neighbouring countries,
such as Saudi Arabia [12, 37]. Moreover, it’s important
to consider the fact that a specific assay has been used
to screen for syphilis (i.e. Treponema pallidum Ab),
which leads to identifying whoever has been infected
with syphilis, whether it is a recent or past infection, and
whether it was treated or not, which may result in over-
estimation of the disease burden [35].
Another serious infectious agent that remains to risks
blood safety is transfusion-associated malaria. The coun-
try is free from local transmission of malaria, and all the
reported cases were imported from abroad, through mi-
grants and travellers from endemic countries. Findings
from our study are consistent with the situation among
the general population, as the rates of positivity for Mal-
aria Ag were found to be higher among Non-Qataris
throughout the years. Moreover, assessing these rates
throughout the year revealed a fluctuating trend. Add-
itionally, the overall positivity rate to the regional
countries showed similar rate to Saudi Arabia, but
higher than the United Emirates and less than
Pakistan [38, 39].
Fig. 4 Positivity rate (%) for TTIs tests combined: (HBsAg, HBcAb, HBV NAT, HCV Ab, INNO-LIA HCV, HCV NAT, HTLV-I/II Ab, INNO-LIA HTLV-I,
Syphilis Ab and INNO-LIA Syphilis, Malaria Ab and Ag tests) of blood donors (Qatari Vs Non-Qatari) in Blood Donors Center at HMC in the
period 2013–2017
Table 3 Temporal trends positivity rate (%) for screening
among blood donors in Blood Donors Center at HMC in the
period 2013–2017
Year 2013 2014 2015 2016 2017 Overall P-value
HCV Ab 0.58 0.58 0.56 0.60 0.70 0.60 0.067
HTLV I/II Ab 0.08 0.16 0.20 0.22 0.23 0.18 < 0.001
Syphilis Ab 0.48 0.49 0.35 0.41 0.45 0.43 0.868
HBsAg 0.34 0.28 0.31 0.26 0.29 0.30 0.256
Malaria Ag 0.14 0.24 0.42 0.10 0.10 0.20 0.523
Screening Tests: (HCV Ab, HBsAg, HTLV I/II Ab, Syphilis Ab and Malaria Ag)
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Finally, it is essential to highlight the fact that the vari-
ance in the prevalence of the transfusion transmissible
infections among blood donors from different countries
can be a reflection of an actual variance of the preva-
lence in these countries, in addition to the different
methods used to test for these infections which can re-
sult in different estimations [40, 41].
In summary, the overall positivity rate of transfusion
transmissible infections among blood donors was assessed
through combined serological in addition to NAT tests,
and results revealed a gradually increasing trend through-
out the years, with 6% increase for each year. However,
this study also revealed fluctuating trends for HBV, HCV,
Syphilis and Malaria. In addition to the increasing trend
for HTLV. Further analysis revealed that rates were higher
among Non-Qataris throughout the years.
Despite the important study findings, some limitations
are worth to be mentioned. Among which is the fact that
this is a retrospective study conducted by utilizing re-
cords in the blood donor centre. The study was limited
to the available data in these records only, which in-
cluded tabulated results of the screening tests by basic
demographics (i.e. age, gender, nationality). Population
data was not available for all basic demographics’ cat-
egories, thus limiting some of the analysis that accounts
for populations changes. Moreover, the study would
have benefited from a longer period exceeding the
current period from 2013 to 2017. Another limitation is
not including data about HIV, due to the sensitivity and
the complexity of these data. Finally, it was not possible
to assess the outcome of donors with positive results for
any of the infections, as the donation records are not
connected with the medical records.
Conclusion
In spite of the previously discussed limitations, this study
still provides important findings that contribute to a bet-
ter understanding of TTIs epidemiology. Up to our
knowledge, this is the first study to assess the prevalence
and trends of TTIs, including HBV, HCV, HTLV, Syph-
ilis and Malaria among blood donors in Qatar. Further
investigations are needed to assess the distribution and
determinants of these infections in the community to
support the development of effective prevention and
control strategies and to protect the community from
potential risks.
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